There is no effective treatment option for the disease, and clinical treatment of GBM is limited by the lack of a scalable, physiologically relevant model for testing therapeutics.
To address these problems, we developed...
NODES is a high-throughput organoid-based drug screening platform to characterize treatment efficacy in common glioma variants.
deep learning pipelines for organoid screening,
oncometabolite mathematical models,
and guidance from patients, clinicians, and other stakeholders
By recapitulating the brain microenvironment, NODES has the potential to accurately characterize drug responses, offering new hope to patients in their fight against this lethal disease.